Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.
- CAS Registry Number
- 2549174-42-5
- Molecular formula
- C28H24FN7O2
- Molecular weight
- 509.54 g/mol
- Drug class
- Selective fibroblast growth factor receptor (FGFR) kinase inhibitortargeted antineoplastic agent
- Mechanism of action
- Lirafugratinib is an oral, selective FGFR inhibitor that targets FGFR2 alterations driving tumour growth. It inhibits FGFR2 kinase signalling, reducing downstream pathway activation in FGFR2 fusion- or rearrangement-positive cholangiocarcinoma. The product label describes it as a kinase inhibitor.
- Indications / reported uses
- Treatment of adults with previously treated, unresectable, locally advanced or metastatic cholangiocarcinoma harbouring an FGFR2 gene fusion or other rearrangement, under the US LYRFIGTU product label (approved September 23, 2026).
Sources: https://www.fda.gov/drugs/cancer-approvals/fda-approves-lirafugratinib-previously-treated-unresectable-locally-advanced-or-metastatic · https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220425Orig1s000lbl.pdf